ZONTIVITY

This brand name is authorized in United States. It is also authorized in Estonia, Lithuania, Romania.

Active ingredients

The drug ZONTIVITY contains one active pharmaceutical ingredient (API):

1	Vorapaxar UNII IN66038E6C - VORAPAXAR SULFATE
	Vorapaxar is a selective and reversible inhibitor of the PAR-1 receptors on platelets that are activated by thrombin.
	Read more about Vorapaxar

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZONTIVITY Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B01AC26		B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin
Discover more medicines within B01AC26

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1676202, 1676213, 1676224, 1676235, 1676246, 1676257
LT	Valstybinė vaistų kontrolės tarnyba	1075820, 1075821, 1075822, 1075823, 1075824, 1075825
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W61976001, W61976002, W61976003, W61976004, W61976005, W61976006
US	FDA, National Drug Code	70347-208